Search Results

You are looking at 91 - 100 of 196 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

management strategy for stage I TC. 14 For stage I nonseminoma, adjuvant chemotherapy with 1 cycle of bleomycin/etoposide/cisplatin (BEPX1) and retroperitoneal lymph node dissection (RPLND) are other options, whereas adjuvant chemotherapy with 1 cycle of

Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

Case Report A 47-year-old Asian woman presented at our institution with stage IIIA (T1cN2M0) invasive ductal carcinoma. She underwent breast-conserving surgery and axillary lymph node dissection. Her tumor was found to be grade II, estrogen

Full access

Philippe E. Spiess

node dissection (ILND) is recommended, and again DSNB is a category 2B recommendation. “We are somewhat cautious in promoting this type of technique [DSNB],” admitted Dr. Spiess. For those with more aggressive primary tumor, the gold standard remains

Full access

Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, Linda C. Wang, and John A. Zic

regional lymph node dissection following the corresponding pathway for the head and neck region (see page 845) or the trunk and extremity region (see page 846). Radiation alone is an alternative when surgery is not initially feasible; however, after

Full access

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

node dissection was associated with improved survival on univariate analysis (HR, 0.8; 95% CI, 0.68–0.94; P =.005), but this parameter was not significant on multivariate analysis. Interestingly, even when examining the more modern subgroup of patients

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

. Int J Gynecol Cancer 2015 ; 25 : 1437 – 1444 . 5. Alagkiozidis I Weedon J Grossman A . Extent of lymph node dissection and overall survival in patients with uterine carcinosarcoma, papillary serous and endometrioid adenocarcinoma: a

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate

Full access

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen

. 7. Lee J Lim DH Kim S . Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial . J

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman

extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study . J Urol 2011 ; 186 : 1261 – 1268 . 23. Gray PJ Fedewa SA Shipley WU . Clinical-pathologic stage

Full access

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

as long as the patient has no contraindications to this treatment. Lymphadenectomy The extent of lymph node dissection needed during radical cystectomy for MIBC is controversial. 8 Data show that a more extensive lymph node dissection may